Feb. 2023 | Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update
Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update Poxel SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months…